Company news

GSK plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GSK 5-in-1 meningitis vaccine recommended in US

April 17, 2025

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices

April 16, 2025

GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025

April 9, 2025

Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older

March 25, 2025

GSK uUTI treatment approved by US FDA

March 25, 2025

Notice of AGM

March 24, 2025

EMA Filing acceptance for Nucala COPD

March 24, 2025

GSK plc 2024 Annual Report on Form 20-F

March 3, 2025

US FDA accept 2 depemokimab indication submissions

March 3, 2025

ANCHOR results presented at 2025 AAAAI

March 3, 2025

GSK publishes Annual Report 2024

February 27, 2025

GSK completes acquisition of IDRx, Inc.

February 24, 2025

GSK plc commences share buyback programme

February 24, 2025

Directorate Change

February 21, 2025

Nucala COPD submission accepted in China

February 20, 2025

GSK 5-in-1 meningitis vaccine approved by US FDA

February 17, 2025

Depemokimab dual filing in China and Japan

January 28, 2025

EMA accepts two submissions for depemokimab

January 28, 2025

EMA accept review Shingrix syringe presentation

January 27, 2025

Jemperli expanded approval in the EU

January 20, 2025

GSK enters agreement to acquire IDRx, Inc.

January 13, 2025

Shingrix fully liquid accepted for US FDA review

January 10, 2025

GSK ADC gets FDA breakthrough therapy designation

January 7, 2025

GSK’s Nucala approved in China for use in CRSwNP

January 3, 2025

Headline results from phase III FIRST trial

December 20, 2024

Jemperli receives US FDA breakthrough designation

December 16, 2024

EMA grants PRIME Designation for GSK’227

December 16, 2024

Jemperli receives positive CHMP opinion

December 16, 2024

Overall survival data presented for Blenrep

December 9, 2024

Blenrep combination China filing acceptance

December 9, 2024

Nucala COPD submission accepted by US FDA

December 9, 2024

Zhifei China collaboration revised and extended

December 5, 2024

GSK liquid meningitis vaccine authorised in EU

November 27, 2024

Blenrep combinations accepted for US FDA review

November 25, 2024

Japan approves first RSV vaccine for adults 50-59

November 22, 2024

GLISTEN Trial of Linerixibat Meets Endpoint

November 19, 2024

GSK announces overall survival results for Blenrep

November 14, 2024

GSK publishes provisional 2025 dividend dates

November 11, 2024

New positive Arexvy data in younger adults at risk

October 24, 2024

FDA accepts new drug application for gepotidacin

October 16, 2024

Positive results of ANCHOR trials of depemokimab

October 14, 2024

Zantac (ranitidine) litigation settlements

October 9, 2024

Positive efficacy data of Arexvy over 3 seasons

October 8, 2024

Positive EU opinion for GSK liquid Menveo vaccine

September 24, 2024

Statement: Zantac (ranitidine) litigation

September 18, 2024

Japan Filing Acceptance: Blenrep Multiple Myeloma

September 17, 2024

China Breakthrough Therapy Designation for Blenrep

September 13, 2024

Positive mRNA flu vaccine Phase II headline data

September 12, 2024

Change of Registered Office

September 11, 2024

Update on phase I/II therapeutic HSV vaccine trial

September 11, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 181 decks. Every deck is listed under its year.